Vol 49, No 4 (2018)
Original Research Article/Praca Oryginalna
Published online: 2018-12-31

open access

Page views 276
Article views/downloads 332
Get Citation

Connect on Social Media

Connect on Social Media

Plerixafor for patients who fail cytokine-or chemotherapy-based stem cell mobilization: Results of a prospective study by the Polish Lymphoma Research Group (PLRG)

Sebastian Giebel1, Sylwia Oborska2, Joanna Romejko-Jarosinska3, Jarosław Dybko4, Joanna Mańko5, Joanna Sawczuk-Chabin6, Agata Szymańska7, Wojciech Legieć5, Anna Czyż8, Magdalena Maruszak8, Maria Saduś-Wojciechowska1, Joanna Drozd-Sokołowska9, Paweł Steckiewicz10, Anna Ejduk6, Ewa Paszkiewicz-Kozik1, Tomasz Ogórka3, Michał Osowiecki1, Łukasz Targoński1, Michał Taszner7
DOI: 10.2478/ahp-2018-0027
Acta Haematol Pol 2018;49(4):234-239.


Autologous hematopoietic stem cell transplantation (autoHSCT) requires collection of sufficient number of hematopoietic stem cells. The goal of this study was to evaluate efficacy of plerixafor used in patients with lymphoid malignancies failing conventional stem cell mobilization.

This was a prospective, non-interventional study. All consecutive patients (n = 109) treated with plerixafor in 11 centers were reported. The drug was used either in case of previous mobilization failure (n = 67) or interventionally, in case of insufficient CD34 cell output during current mobilization (n = 42). Successful mobilization was defined as resulting in collection of ≥ 2 × 10 CD34 cells/kg for single autoHSCT or ≥ 4 × 10 CD34 cells/kg for double procedure.

The overall rate of successful mobilization was 55% (55% for single and 56% for double autoHSCT). The median total number of collected CD34 cells/kg was 2.4 (range, 0-11.5) for patients intended for a single transplantation while 4.0 (0.6-16.9) for double procedure. The number of circulating CD34 cells increased after the use of plerixafor regardless of baseline values. The median fold increase was 3.3 (0.3-155). Data from this observational study confirm high efficacy of plerixafor used in routine clinical practice as salvage for patients with lymphoid malignancies failing conventional stem cell mobilization.

Article available in PDF format

View PDF Download PDF file